glp 1 drugs depression Transformation 2.0: The GLP-1 RAs as Psychiatric Medications? Ozempic and other GLP-1 drugs

GLUCAGON-LIKE PEPTIDE RECEPTOR AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR AGONISTS These medications act by mimicking endogenous incretins peptide hormones secreted by the gastrointestinal system, controlled by neural mechanisms

PSM with age, sex, race, and disease comorbidities was then conducted, yielding 162,253 matched patients for analysis

The Beneficiaries of GLP-1 Drugs Across Industries Health Insurers and the Cost of Obesity Source: McKinsey 4 Although weight loss has been the main focus in the analyses of these drugs so far, it is important to bear in mind that with them comes the improvement in other measurements of health, such as blood glucose levels, cardiovascular parameters, cholesterol and triglyceride levels

For example, the SELECT trial clearly demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023

The ADA highlights the benefits of combining GLP-1 receptor agonists with SGLT2 inhibitors, stating: Combined use [of GLP-1 RAs and SGLT2 inhibitors] may be considered for additive cardio-kidney protection